Skip to main content

Advertisement

Figure 2 | Molecular Cancer

Figure 2

From: Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

Figure 2

P-gp expression levels in the Doctaxel resistant cell lines. A. Total cellular protein was extracted from the cells and 50 μg was assessed by western blotting. P-gp was not expressed in the PC-3 Ag, PC-3 D8, PC-3 D12 sublines or the DLKP (40 μg) negative control cell line, but was expressed in the DLKP-A (5 μg) drug resistant variant of the DLKP cell line. β-actin the house keeping protein was used as loading control for P-Gp. B. The PC-3 Ag, PC-3 D12 and NCI-ADR/RES cells lines were treated with Docetaxel (20 nM) alone or in the presence of the P-gylcoprotein inhibitor Elacridar (0.25 and 0.5 μM) and Docetaxel (20 nM) and assessed for apoptosis by flow cytometry. An independent samples t-test was used to compare the average percentage of apoptosis between the control groups and each of the treated groups for the PC-3 Ag, PC-3 D12 and NCI-ADR/RES cell lines *p- < 0.05. C. Total cellular protein was extracted from the cells and 50 μg was assessed by western blotting. P-Gp was weakly expressed in the DU-145 R and strongly expressed in the 22RV1 R sublines. No expression was seen in the Aged matched. β-actin the house keeping protein was used as loading control for p-glycoprotein. D. The DU-145 Ag, DU-145 R and 22RV1 Ag and 22RV1 R cells lines were treated with Docetaxel (20 nM) alone, or the P-Gp inhibitor Elacridar (0.25 μM) alone or in the presence of Elacridar (0.25 μM) and Docetaxel (20 nM) and assessed for apoptosis by flow cytometry. Blots shown are representative of three independent experiments.

Back to article page